NRF2 activation may be a potential therapeutic approach to counteracting the NLRP3 inflammasome, which can be used for PD and COVID-19 by simultaneously reducing neuroinflammation and systemic inflammation [90]. The gene discussed is NLRP3; the disease is Parkinson disease.